Oruka Therapeutics
ORKA90.2002.13% ( -1.960 )
Oruka Therapeutics (ORKA)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and othe...
- Open
- 91.700
- High
- 93.500
- Low
- 89.370
- Prev. Close
- 92.160
- Volume
- 744.54K
- Turnover
- 67.71M
- Avg Price
- 90.937
- Bid/Ask Ratio
- --
- Amplitude
- 4.48%
- 52wk High
- 97.780
- Volume Ratio
- 0.97
- Turnover Ratio
- 2.18%
Oruka Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$148.1764.26%
Forecast & RatingStrong buy
13analysts
- Strong buy84.62%
- Buy15.38%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- US Stock Market Update · Jul 17 at 02:40 PM
Oruka Therapeutics Surges 10% During Regular Trading on Analyst Upgrades
- US Stock Market Update · Jul 17 at 12:33 PM
Oruka Therapeutics (ORKA) surges 11% on analyst upgrade
- US Stock Market Update · Jul 17 at 09:31 AM
Oruka Therapeutics Surges 8% During Regular Trading on Analyst Upgrade
- PUBT · Jul 15 at 06:37 PM
Oruka Therapeutics CMO Joana Goncalves disposes of 7,000 common shares for $601,227.73
- PUBT · Jul 13 at 04:10 PM
Oruka Therapeutics SVP Finance Arjun Agarwal sells USD 840,975 in common shares
- MSN · Jul 10 at 06:43 PM
HMI Capital pares its stake in AI company nCino
